|
TOP
|
|
XGEVA(denosumab) injection
|
HIGHLIGHTS OF PRESCRIBING INFORMATION |
These highlights do not include all the information needed to use XGEVA™ safely and effectively. See full prescribing information for XGEVA.
Xgeva (denosumab)
injection, for subcutaneous use
Initial U.S. Approval: 2010
|
|
INDICATIONS AND USAGE
|
|
Xgeva is a RANK ligand (RANKL) inhibitor indicated for:
-
Prevention of skeletal-related events in patients with bone metastases from solid tumors (1.1)
Important limitation of use: Xgeva is not indicated for the prevention of skeletal-related events in patients with multiple myeloma (1.2)
|
|
DOSAGE AND ADMINISTRATION
|
-
Administer 120 mg every 4 weeks as a subcutaneous injection in the upper arm, upper thigh, or abdomen (2.1)
-
Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia (2.1)
|
|
DOSAGE FORMS AND STRENGTHS
|
-
120 mg/1.7 mL (70 mg/mL) single-use vial (3)
|
|
CONTRAINDICATIONS
|
|
| |
